🟢 Revvity is trading 4.2% up today after announcing CE-IVDR-certified type 1 diabetes screening kit

Revvity is trading 4.2% up at $148.06 after announcing its GSP T1D 3plex kit, a CE-IVDR-certified solution designed to detect children at risk of type 1 diabetes before symptoms appear.

• The product will initially be available in Europe and other markets accepting CE IVD-marked products.
• Healthcare-sector strength and biotech optimism may provide additional support, while broader markets are weaker.